GlassScriptPhysician profile
Chloe Lan Russo
NPI 1528300639
$3,171.59
in general payments reported to CMS, 2019-2025
27 companies · $1,015 in 2025
The $1,015 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $262 · 2021: $265 · 2022: $120 · 2023: $375 · 2024: $816 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,067.17 |
| Education | $138.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $687.82 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $351.93 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $281.87 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $253.44 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Optinose US, INC. | $208.28 | 2019-2025 | |
| Amgen INC. | $196.55 | 2022-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $186.38 | 2023-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $144.89 | 2020-2024 | Takhzyro, Hyqvia, Cuvitru |
| Csl Behring | $136.44 | 2019-2025 | Hizentra |
| Grifols USA, LLC | $120.98 | 2023-2025 | Xembify |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Novartis Pharmaceuticals Corporation | $89.33 | 2024-2025 | |
| Kaleo, INC. | $68.05 | 2019-2020 | |
| Pfizer INC. | $44.33 | 2023-2025 | |
| Covis Pharma Gmbh | $43.52 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $41.20 | 2019 | |
| Ionis Pharmaceuticals, INC. | $27.37 | 2025 | |
| Aimmune Therapeutics, INC. | $24.76 | 2021 | |
| Pharming Healthcare, INC. | $24.66 | 2025 | Ruconest |
| Arcutis Biotherapeutics, INC. | $22.13 | 2024 | Zoryve |
| Jubilant Hollisterstier LLC | $21.70 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.79 | 2019 | |
| Organon LLC | $18.55 | 2025 | |
| Genentech, INC. | $15.88 | 2023 | Xolair |
| Merck Sharp & Dohme LLC | $15.32 | 2023 | |
| Phadia US INC. | $14.11 | 2019 | |
| Horizon Therapeutics Plc | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.